Effect of estramustine phosphate on hormone refractory prostate cancer

Acta Urologica Japonica

Volumn 43, Issue 3, 1997, Pages 245-250

  Tanaka, Masashi ^a   Shiomi, Kou ^a   Hamano, Satoshi ^a   Suzuki, Noriyuki ^a   Igarashi, Tatsuo ^a   Murakami, Shino ^a   Shimazaki, Jun ^b  

^a ASAHI GENERAL HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

estramustine phosphate; hormone refractory prostate cancer

Indexed keywords

ESTRAMUSTINE PHOSPHATE;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EDEMA; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PROSTATE CANCER; SURVIVAL;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0031011556     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Soloway MS, Hardem SW, Hickey D, et al.: Stratification of patients with metastatic prostatic cancer based on extent of disease on initial bone scan. Cancer 61: 195-202, 1988
2. Sandberg AA: Metabolic parameters of estracyt pertinent to its effects in prostatic cancer. Urology 23: 11-21, 1984
3. Forshell GP, Muntzing JEkA, Lindstedt E, et al.: The absorption, metabolism and excretion of Emcyt (NCS89199) in patients with prostatic cancer. Invest Urol 14: 128-132, 1976
4. Von Hoff D, Rozencweig M, Slavik M, et al.: Estramustine phosphate: a specific chemotherapeutic agent? J Urol 117: 464, 1977
5. Wakisaka M, Iwasaki I and Shimazaki J: Effect of estracyt on the transplantable tumors of mice. Urol Res 7: 291-298, 1979
6. Yamanaka H, Shimazaki J, Imai K, et al.: Effect of estracyt on the rat prostate. Invest Urol 14: 400, 1977
7. Smith PH, Robinson MRG, Richards B, et al.: A comparison of the effect of diethylstilbesterol with low dose estramustine phosphate in the treatment of advanced prostatic cancer : final analysis of a phase III trial of the European organization for research on treatment of cancer. J Urol 136 : 619-623, 1986
8. Bjork P, Forsgren B, Gustafsson JA, et al.: Partical charactarization and quantitation of a human prostatic estramustine binding protein. Cancer Res 42: 1935-1942, 1982
9. Norlen BJ, Anderson SB, Bjork P, et al.: Uptake of estramustine phosphate (Estracyt) metabolites in prostatic cancer. J Urol 140: 1058-1062, 1988
10. Stearns ME and Tew KD: Antimicrotubule effects of estramustine on anti-prostatic tumor drug. Cancer Res 45: 3891-3897, 1985
11. Dahllof B, Billstrom A, Cabrai F, et al.: Estramusrine depolymerizes microtubules by binding to tubulin. Cancer Res 53: 4573-4581, 1993
12. Amato R: Logothetis of a phase II trial of estramustine and vincristine for patients with progressive hormone refractory prostate cancer. Proc AACR 32: 186, 1991
13. Yagoda A and Petrylak D: Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 71 : 1098-1109, 1993
14. Perry CM and McTavish D: Estramustine phosphate sodium. Drugs Aging 7: 49-74, 1995
15. Kreis W: Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest 13: 296-312, 1995
16. Akimoto S, Ohki T, Akakura K, et al.: Chemotherapy for endocrine-therapy-refractory prostate cancer. Cancer Chemother Pharmacol 35: 18-22, 1994
17. Isaka S, Teshima S, Akakura K., et al.: Histological effects of endocrine therapy for prostatic cancer in relation to clinical course. Jpn J Clin Oncol 19: 258-264, 1989
18. Ohki T, Akakura K, Ueda T, et al.: Changes in histologic grade and argyrophilic nucleolar organizer resions during progression of prostate cancer. Jpn J Clin Oncol 26: 82-87, 1996
19. Akimoto S, Masai M, Akakura K, et al.: Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur Urol 27: 207-212, 1995
20. Dupon A, Gomez J-L, Cusan L, et al.: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150: 908-913, 1993
21. Akakura K, Akimoto S, Ohoki T, et al.: Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidalantiandrogen chlormadinone acetate. Urology 45: 700-705, 1995
22. Hudes GR, Greenberg R, Krigel RL, et al.: Plase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10: 1754-1761, 1992
23. Pienta KJ, Redman BG, Hussain M, et al.: Inhibition of prostate cancer growth by estramustine and etoposide. Cancer 75 Suppl: 1920-1926, 1995